Vivo Bio Tech Past Earnings Performance
Past criteria checks 2/6
Vivo Bio Tech's earnings have been declining at an average annual rate of -4.9%, while the Life Sciences industry saw earnings growing at 8.8% annually. Revenues have been declining at an average rate of 2% per year. Vivo Bio Tech's return on equity is 7.4%, and it has net margins of 8%.
Key information
-4.9%
Earnings growth rate
-9.8%
EPS growth rate
| Life Sciences Industry Growth | 11.2% |
| Revenue growth rate | -2.0% |
| Return on equity | 7.4% |
| Net Margin | 8.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Vivo Bio Tech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 485 | 39 | 212 | 0 |
| 30 Sep 23 | 491 | 27 | 216 | 0 |
| 30 Jun 23 | 525 | 25 | 236 | 0 |
| 31 Mar 23 | 522 | 26 | 237 | 0 |
| 31 Dec 22 | 528 | -1 | 247 | 0 |
| 30 Sep 22 | 522 | 11 | 247 | 0 |
| 30 Jun 22 | 497 | 13 | 258 | 0 |
| 31 Mar 22 | 514 | 22 | 239 | 0 |
| 31 Dec 21 | 522 | 32 | 272 | 0 |
| 30 Sep 21 | 511 | 41 | 259 | 0 |
| 30 Jun 21 | 556 | 59 | 268 | 0 |
| 31 Mar 21 | 518 | 57 | 268 | 0 |
| 31 Dec 20 | 500 | 50 | 247 | 0 |
| 30 Sep 20 | 523 | 40 | 285 | 0 |
| 30 Jun 20 | 512 | 42 | 278 | 0 |
| 31 Mar 20 | 554 | 44 | 321 | 0 |
| 31 Dec 19 | 548 | 19 | 227 | 0 |
| 30 Sep 19 | 551 | 18 | 227 | 0 |
| 30 Jun 19 | 554 | 15 | 227 | 0 |
| 31 Mar 19 | 558 | 22 | 324 | 0 |
| 31 Mar 18 | 470 | 31 | 172 | 0 |
| 31 Mar 17 | 341 | 25 | 181 | 0 |
| 31 Mar 16 | 286 | 9 | 131 | 0 |
| 31 Mar 15 | 178 | 5 | 98 | 0 |
| 31 Mar 14 | 161 | 3 | 99 | 0 |
Quality Earnings: 511509 has high quality earnings.
Growing Profit Margin: 511509 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 511509's earnings have declined by 4.9% per year over the past 5 years.
Accelerating Growth: 511509 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 511509 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).
Return on Equity
High ROE: 511509's Return on Equity (7.4%) is considered low.